R&D channel feed – Endpoints News

R&D channel feed

Art Krieg’s Checkmate executes a snappy 1-2 biotech gambit — big crossover followed by an instant IPO

5 years ago

UK biotech rockets up on Covid-19 'breakthrough' for inhaled interferon beta — can its small study live up to the boast?

5 years ago

J&J-partnered MeiraGTx aims at Biogen with new eye gene therapy data

5 years ago

A Jennifer Doudna-led team finds a new CRISPR enzyme in the giant viruses of a California mud bog

5 years ago

In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan

5 years ago

Eli Lilly’s mirikizumab joins the club beating up on Cosentyx as another head-to-head study leaves Novartis’ drug in the dust

5 years ago

Full Brilinta study results show the blood thinner reduces rate of secondary stroke

5 years ago

Gilead's ex-R&D chief Bischofberger heads back to the biotech giant to pick up a pair of late-stage drugs that had been put aside

5 years ago

The $1B Merck-Bayer drug that divided cardiologists in March gets priority review

5 years ago

A day after Moderna vaccine results, rumors swirl of pending AstraZeneca data

5 years ago

MilliporeSigma to build new $20 million, 12,000-square-foot lab in Switzerland

5 years ago

'Longevity as a service': Insilico spins off AI biotech that trains deep learning on anti-aging treatments

5 years ago

NIAID and Moderna spell out a 'robust' immune response in PhI coronavirus vaccine test — but big questions remain to be answered

5 years ago

Why pay $4B for a steady diet of disappointment? Porges turns thumbs down on Alexion’s M&A strategy, offers some pointers

5 years ago

Cytokinetics nabs Chinese partner, up to $450M as CV becomes company focus

5 years ago

Engineering an on/off switch for CAR-T out of yeast and Jurassic Park

5 years ago

Playing catch-up, Roche outlines plans for a PhIII hemophilia A program — next year

5 years ago

Covid-19 roundup: CanSino eyes more overseas PhIII sites as Canada trial reportedly stalls; Indian drugmaker surges on 30-person data

5 years ago

Roche’s PD-L1 player Tecentriq fails PhIII for ovarian cancer

5 years ago

Two years after a ‘positive’ result tanked their stock, Ovid's Jeremy Levin wins a partner for the PhIII journey

5 years ago

Gilead boasts of positive remdesivir data on mortality — but their analysis provokes the skeptics

5 years ago

After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought

5 years ago

The home run count: The $100M+ mega-round boom in biotech inspired a $7.3B feeding frenzy — so far this year

5 years ago

Stanford star oncology scientist Ed Engleman helped create the immunotherapy field. Now he wants to shake up neurodegeneration R&D

5 years ago

First page Previous page 195 196 197198199 200 201 Next page Last page